Side Effects of Pulmonary Hypertension Medications
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any - 18 |
| Updated: | 9/30/2018 |
| Start Date: | August 2011 |
| End Date: | December 2020 |
| Contact: | Jeffrey Feinstein, MD, MPH |
| Email: | jeff.feinstein@stanford.edu |
| Phone: | 650 723 7913 |
Patient Reported Side Effects of Pulmonary Hypertension (PH) Medications
The study seeks to analyze the patient reported effects of pulmonary hypertension medications
and compare these with the side effects described on the package inserts. Side effects for
these PH medications have been described in the adult population, but have never been
described in the pediatric population. This information can better improve patient care and
be used to characterize the side effects resultant from these medications.
and compare these with the side effects described on the package inserts. Side effects for
these PH medications have been described in the adult population, but have never been
described in the pediatric population. This information can better improve patient care and
be used to characterize the side effects resultant from these medications.
As part of standard of care, patients are routinely asked about any symptoms they might be
experiencing. This study seeks to quantify these symptoms for research purposes. Participants
will be identified through those who attend the pediatric pulmonary hypertension clinic at
LPCH. Only children who are currently on one of seven PH medications (Bosentan, Epoprostenol,
Letairis, Sildenafil, Tadalafil, Treprostinil, Ventaris) will be approached. Patients who
consent to be in the study will answer a brief series of questions pertaining to the presence
and duration of their symptoms. These will be correlated to a list of side effects taken from
Lexicomp (a medication database).
experiencing. This study seeks to quantify these symptoms for research purposes. Participants
will be identified through those who attend the pediatric pulmonary hypertension clinic at
LPCH. Only children who are currently on one of seven PH medications (Bosentan, Epoprostenol,
Letairis, Sildenafil, Tadalafil, Treprostinil, Ventaris) will be approached. Patients who
consent to be in the study will answer a brief series of questions pertaining to the presence
and duration of their symptoms. These will be correlated to a list of side effects taken from
Lexicomp (a medication database).
Inclusion Criteria:
- pulmonary hypertension
- currently taking at least one of the following PH medications (Bosentan, Epoprostenol,
Letairis, Sildenafil, Tadalafil, Treprostinil, Ventaris)
Exclusion Criteria:
- >18 years
We found this trial at
1
site
Stanford, California 94305
Principal Investigator: Jeffrey Feinstein, MD, MPH
Phone: 650-723-7913
Click here to add this to my saved trials
